Is the open mouth mightier than the needle? uri icon

Overview

abstract

  • In this issue of Blood, Bernard et al provide evidence that ibrutinib, the orally administered inhibitor of Bruton tyrosine kinase (BTK), crosses the blood-brain barrier and has activity against mantle cell lymphoma (MCL) in the central nervous system (CNS).

publication date

  • October 1, 2015

Research

keywords

  • Antineoplastic Agents
  • Central Nervous System Neoplasms
  • Lymphoma, Mantle-Cell
  • Pyrazoles
  • Pyrimidines

Identity

Scopus Document Identifier

  • 84947903827

Digital Object Identifier (DOI)

  • 10.1182/blood-2015-08-664060

PubMed ID

  • 26429964

Additional Document Info

volume

  • 126

issue

  • 14